Literature DB >> 30310476

New Advances in the Management of Refractory Angina Pectoris.

Kevin Cheng1,2, Ranil de Silva1,3.   

Abstract

Refractory angina is a significant clinical problem and its successful management is often extremely challenging. Defined as chronic angina-type chest pain in the presence of myocardial ischaemia that persists despite optimal medical, interventional and surgical treatment, current therapies are limited and new approaches to treatment are needed. With an ageing population and increased survival from coronary artery disease, clinicians will increasingly encounter this complex condition in routine clinical practice. Novel therapies to target myocardial ischaemia in patients with refractory angina are at the forefront of research and in this review we discuss those in clinical translation and assess the evidence behind their efficacy.

Entities:  

Keywords:  Chest pain; angina pectoris; cell therapy; clinical trials; coronary sinus reducer; external enhanced counterpulsation; extracorporeal shockwave therapy; innovation; myocardial ischaemia; refractory angina pectoris; stem cells

Year:  2018        PMID: 30310476      PMCID: PMC6159415          DOI: 10.15420/ecr.2018:1:2

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN: 1758-3756


  94 in total

1.  Scientific basis for the surgical treatment of coronary artery disease.

Authors:  C S BECK; D S LEIGHNINGER
Journal:  J Am Med Assoc       Date:  1955-11-26

2.  2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Stephan D Fihn; James C Blankenship; Karen P Alexander; John A Bittl; John G Byrne; Barbara J Fletcher; Gregg C Fonarow; Richard A Lange; Glenn N Levine; Thomas M Maddox; Srihari S Naidu; E Magnus Ohman; Peter K Smith
Journal:  Circulation       Date:  2014-07-28       Impact factor: 29.690

3.  Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial.

Authors:  Shuta Ishigami; Shinichi Ohtsuki; Suguru Tarui; Daiki Ousaka; Takahiro Eitoku; Maiko Kondo; Michihiro Okuyama; Junko Kobayashi; Kenji Baba; Sadahiko Arai; Takuya Kawabata; Ko Yoshizumi; Atsushi Tateishi; Yosuke Kuroko; Tatsuo Iwasaki; Shuhei Sato; Shingo Kasahara; Shunji Sano; Hidemasa Oh
Journal:  Circ Res       Date:  2014-11-17       Impact factor: 17.367

4.  First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease.

Authors:  Francesco Giannini; Luca Baldetti; Alfonso Ielasi; Neil Ruparelia; Francesco Ponticelli; Azeem Latib; Satoru Mitomo; Antonio Esposito; Anna Palmisano; Alaide Chieffo; Antonio Colombo
Journal:  JACC Cardiovasc Interv       Date:  2017-09-25       Impact factor: 11.195

5.  The beneficial effect of extracorporeal shockwave myocardial revascularization in patients with refractory angina.

Authors:  Gianluca Alunni; Sebastiano Marra; Ilaria Meynet; Maurizio D'amico; Pelloni Elisa; Annalaura Fanelli; Stefano Molinaro; Paolo Garrone; Armando Deberardinis; Mario Campana; Amir Lerman
Journal:  Cardiovasc Revasc Med       Date:  2014-11-10

6.  Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).

Authors:  Hung-Fat Tse; Sukumaran Thambar; Yok-Lam Kwong; Philip Rowlings; Greg Bellamy; Jane McCrohon; Paul Thomas; Bruce Bastian; John K F Chan; Gladys Lo; Chi-Lai Ho; Wing-Sze Chan; Raymond Y Kwong; Anthony Parker; Thomas H Hauser; Jenny Chan; Daniel Y T Fong; Chu-Pak Lau
Journal:  Eur Heart J       Date:  2007-11-05       Impact factor: 29.983

7.  Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits.

Authors:  Keiji Oi; Yoshihiro Fukumoto; Kenta Ito; Toyokazu Uwatoku; Kohtaro Abe; Takatoshi Hizume; Hiroaki Shimokawa
Journal:  Tohoku J Exp Med       Date:  2008-02       Impact factor: 1.848

8.  A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.

Authors:  Thomas J Povsic; Candice Junge; Adel Nada; Richard A Schatz; Robert A Harrington; Charles J Davidson; F David Fortuin; Dean J Kereiakes; Farrell O Mendelsohn; Warren Sherman; Gary L Schaer; Christopher J White; Duncan Stewart; Kenneth Story; Douglas W Losordo; Timothy D Henry
Journal:  Am Heart J       Date:  2013-04-19       Impact factor: 4.749

9.  Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease.

Authors:  Piero O Bonetti; Gregory W Barsness; Paul C Keelan; Theresa I Schnell; Geralyn M Pumper; Jeffrey T Kuvin; Robert P Schnall; David R Holmes; Stuart T Higano; Amir Lerman
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

10.  Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

Authors:  Douglas W Losordo; Richard A Schatz; Christopher J White; James E Udelson; Vimal Veereshwarayya; Michelle Durgin; Kian Keong Poh; Robert Weinstein; Marianne Kearney; Muqtada Chaudhry; Aaron Burg; Liz Eaton; Lindsay Heyd; Tina Thorne; Leon Shturman; Peter Hoffmeister; Ken Story; Victor Zak; Douglas Dowling; Jay H Traverse; Rachel E Olson; Janice Flanagan; Donata Sodano; Toshinori Murayama; Atsuhiko Kawamoto; Kengo Fukushima Kusano; Jill Wollins; Frederick Welt; Pinak Shah; Peter Soukas; Takayuki Asahara; Timothy D Henry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.